Table I.
Summary of spontaneous clinical paralyses in C57BL/6 2D2 TNFR2−/− and TNF−/− mice.
| Genotype | Gender | % Incidencea | Mean Day of Onsetb | Mean Peak Scorec |
|---|---|---|---|---|
| 2D2 TNFR−/− | ♀ | 92(59/64) | 48.6 ± 1.5 | 3.88 ± 0.04 |
| 2D2 TNFR−/− | ♂ | 8.3 (5/60) | 75.2 ± 2.6 | 3.00 ± 0.09 |
| 2D2 TNF−/− | ♀ | 7.9 (5/63) | 86.6 ± 2.4 | 2.80 ± 0.11 |
| 2D2 TNF−/− | ♂ | 7.2 (4/55) | 85.8 ± 2.9 | 2.50 ± 0.08 |
| 2D2 TNFR−/− | ♀ | 7.5 (3/40) | 87.7 ± 1.1 | 2.33 ± 0.09 |
| 2D2 TNFR−/− | ♂ | 4.1 (1/24) | 79.0 | 2 |
| 2D2 TNFR−/− | ♀ | 6.8 (5/73) | 87.0 ± 1.7 | 2.40 ± 0.06 |
| 2D2 TNFR−/− | ♂ | 5.5 (4/72) | N.D. | N.D. |
a
The % incidence was calculated by dividing the number of mice that developed clinical paralyses within 6-mo-of-age by the total number of mice scored in the group.
b
The mean day of onset (mean ± SEM) was calculated by adding the first day of clinical signs of individual mice and dividing with the number of mice in the group, not including mice that did not develop EAE.
c
The mean peak score (mean ± SEM) was calculated by adding the peak scores of individual mice and dividing by the number of mice in each group. Mice that did not develop clinical symptoms of paralyses were not included in the analyses.